Morpholinium-3-methyl-1,2,4-triazolyl-5-thioacetate in comprehensive correction of cognitive impairment in patients with acute myocardial infarction

Abstract

The paper deals with the study of morpholinium-3-methyl-1,2,4-triazolyl-5-thioacetate impact in correction of cognitive disorders in patients with acute myocardial infarction. The study enrolled 70 patients with acute myocardial infarction and cognitive impairment aged up to 60 years without burdened neurological history. Cognitive disorders were revealed by means of cognitive dysfunction tests (Mini-Mental State Examination, clock drawing test, 10 words memorizing). Additionally, C-reactive protein and blood cortisol content was assessed (day 1 and day 10 of the disease). Depending on the type of treatment, the patients were divided into 2 groups: group 1 (n = 35) — standard treatment scheme in acute myocardial infarction, group 2 (n = 35) — standard treatment in combination with morpholinium 3-methyl-1,2,4-triazolyl-5 thioace­tate. During the study, the patients showed increased cortisol and C-reactive protein levels within the first 24 hours of the di­sease — 12.10 ± 0.04 and 8.20 ± 0.01, respectively. During the treatment, group 1 was revealed to have a decrease in cortisol levels to 10.90 ± 0.04, while patients of group 2 had significant reduction of cortisol content to 8.20 ± 0.04 (Р < 0.05). C-reactive protein values in group 2 were reduced to 5.10 ± 0.01, while in group 1 they were within the range of 8.10 ± 0.01 (Р < 0.05). The test outcomes have shown that cognitive dysfunction mani­fests in the form of attributable cognitive impairment in 59 %, mild dementia — in 21 %, moderate dementia — in 20 % of patients with acute myocardial infarction within the first 24 hours of the disease. Morpholinium 3-methyl-1,2,4-triazolyl-5 thioacetate added to standard treatment scheme resulted in significantly decreased cognitive dysfunction in 73 % of patients, while in patients who underwent standard treatment, regression of cognitive impairment was revealed only in 46 % of cases. The study has made it possible to establish that application of morpholinium 3-methyl-1,2,4-triazolyl-5 thioacetate contributes to a significant improvement of cognitive dysfunction, while in patients who underwent standard treatment, regression of cognitive impairment was substantially decreased. The paper deals with issues concerning improvement of diagnosis and optimization of management of cerebral insufficiency in patients with acute myocardial infarction.